指南与共识MDS 与骨髓增殖性肿瘤造血干细胞移植与细胞治疗血栓与止血

意义未明克隆性造血与未确定意义克隆性血细胞减少:2026年临床关联与管理建议更新

Clonal Hematopoiesis of Indeterminate Potential and Clonal Cytopenias of Undetermined Significance: 2026 Update on Clinical Associations and Management Recommendations.
指南 / 共识 · Am J Hematol · 2026-01-08

该指南更新阐述了意义未明克隆性造血(CHIP)的操作性定义,即造血干/祖细胞中致癌驱动基因致病变异且等位基因频率≥2%。CHIP与进行性血细胞减少、血液肿瘤、血细胞增多及动脉粥样硬化性心脑血管病等非血液疾病相关。管理推荐关注治疗相关髓系肿瘤中TP53、PPM1D和/或CHEK2克隆的选择优势,并探讨CH评估在持续不明原因血细胞减少、化疗/放疗前、自体移植或CAR-T前筛查及胚系嵌合变异排查中的角色。

要点

  • CHIP定义为造血干/祖细胞中致癌驱动基因致病变异且VAF≥2%。
  • CH与进行性血细胞减少、血液肿瘤及心脑血管病等多种疾病相关。
  • TP53、PPM1D和/或CHEK2克隆在治疗相关髓系肿瘤中具有选择优势。

核心结论

  • CHIP与多种血液及非血液疾病风险增加相关,其评估在特定临床场景中具有潜在价值。

研究设计与样本

  • 本文件为Am J Hematol发布的指南更新,制定机构与方法未在原文中报告。

主要发现

  • CHIP操作性定义为造血干/祖细胞中致癌驱动基因致病变异且等位基因频率≥2%。
  • CH与进行性血细胞减少(即未确定意义克隆性血细胞减少)、血液肿瘤(主要为髓系,也含淋系)、血细胞增多(包括单核细胞增多)及动脉粥样硬化性心脑血管病相关。
  • CH还与静脉血栓栓塞、2型糖尿病、慢性阻塞性肺疾病、骨质疏松和痛风等多种疾病相关,对阿尔茨海默病可能具有保护作用。
  • 在治疗相关髓系肿瘤中,TP53、PPM1D和/或CHEK2基因的 antecedent CH克隆具有明确选择优势。

关键数值与推荐

  • CHIP诊断标准:造血干/祖细胞中致癌驱动基因致病变异,变异等位基因频率≥2%。
  • 持续(≥4个月)不明原因血细胞减少者建议进行CH评估。
  • 恶性肿瘤患者接受辅助细胞毒化疗和/或放疗或放射性核素治疗前、自体造血干细胞移植或CAR-T治疗前筛查、以及胚系嵌合变异排查时,可考虑CH评估。

临床怎么用

  • 对持续≥4个月不明原因血细胞减少的患者,可进行CH评估以辅助诊断未确定意义克隆性血细胞减少。
  • 对拟接受辅助细胞毒化疗和/或放疗、自体造血干细胞移植或CAR-T治疗的患者,可考虑CH评估以识别治疗相关髓系肿瘤高风险克隆。
  • 在排查潜在胚系嵌合变异时,CH评估有助于区分克隆性造血与胚系变异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONDITION OVERVIEW: Clonal hematopoiesis (CH) refers to the presence of somatic variants in hematopoietic stem and progenitor cells (HSPC) that result in expansion over time. DIAGNOSIS: CH of indeterminate potential (CHIP) is operationally defined as pathogenic variants in oncogenic driver genes occurring in HSPCs at variant allele frequencies ≥ 2%. CLINICAL ASSOCIATIONS: CH is associated with increased risk for progressive cytopenias (also called clonal cytopenia of undetermined significance), hematological (predominantly myeloid but also lymphoid) neoplasms, cytosis (including monocytosis), and nonhematological conditions such as atherosclerotic cardiovascular and cerebrovascular disease. CH is linked to numerous other diseases including venous thromboembolism, type 2 diabetes mellitus, chronic obstructive pulmonary disease, osteoporosis, and gout, with a potential protective impact in Alzheimer's disease (AD). MANAGEMENT RECOMMENDATIONS: CH detection is becoming increasingly common due to the ubiquitous use of somatic and germline sequencing in clinical practice, particularly, in oncology. The clinical implications of CH are most relevant in therapy-related myeloid neoplasms (t-MN), with antecedent CH clones in genes such as TP53, PPM1D, and/or CHEK2 having a clear selection advantage. Furthermore, genetic predisposition to CH has provided some clarity on the origin and evolution of CH. We are currently defining the role for CH assessment in individuals with persistent (≥ 4 months) unexplained cytopenias, in patients with malignancies prior to adjuvant cytotoxic chemotherapy and/or radiation or radionuclide therapy, screening prior to autologous hematopoietic stem cell transplantation or chimeric antigen receptor T cell (CAR-T) therapy, and to work-up potentially germline mosaic variants.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Mangaonkar AA, Bolton KL, Patnaik MM, et al. Clonal Hematopoiesis of Indeterminate Potential and Clonal Cytopenias of Undetermined Significance: 2026 Update on Clinical Associations and Management Recommendations. Am J Hematol. 2026. PMID: 41508691. doi:10.1002/ajh.70205

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。